Oligonucleotide therapeutics are unlocking historically inaccessible disease targets. WuXi AppTec accelerates oligonucleotide drug discovery for central nervous system (CNS) diseases through an integrated discovery platform that bridging key capabilities required to move efficiently from target biology to candidate selection. This approach reduces discovery complexity and enables faster progression of promising programs...

Antibody-drug conjugates (ADCs) continued to expand into first-line and earlier-stage treatment settings in Q2 2026. Regulatory progress, together with the first approval of a bispecific ADC, showed that the modality is broadening both clinically and in terms of molecular design...

Oligonucleotide therapeutics continued to mature in Q2 2026, supported by regulatory progress across lipid disorders, chronic hepatitis B, neurological diseases, neuromuscular conditions, and rare genetic disorders...

WuXi AppTec has built the Direct-to-Biology (D2B) system, which integrates years of expertise such as medicinal chemistry, high-throughput chemistry, high-throughput screening, and computer-aided drug design into a continuous workflow. With D2B capability, the design-synthesis-test cycle of a molecular glue program can be compressed from months to 2-3 weeks...

By adapting established reactions and introducing new molecular scaffolds into DNA-Encoded Library (DEL) systems, WuXi AppTec expands the chemical space available for molecular exploration, enabling clients to advance drug discovery...

To address the industry-wide challenge of macrocycle synthesis, WuXi AppTec has developed a systematic solution through years of continuous effort. The team has assembled a technical toolbox of over 20 representative cyclization methods to address the key hurdles in macrocycle synthesis, enabling flexible selection of the optimal synthetic route based on molecular structural characteristics, and thereby effectively improving synthesis success rates and overall efficiency...